Clarivate Epidemiology's coverage of Cystic Fibrosis (CF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CF for each…
Clarivate Epidemiology's coverage of Cystic Fibrosis (CF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CF for each…
Clarivate Epidemiology's coverage of Cystic Fibrosis (CF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CF for each…
Clarivate Epidemiology's coverage of cystic fibrosis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of cystic fibrosis…
Clarivate Epidemiology's coverage of Cystic Fibrosis (CF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CF for each…
A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially…
MARKET OUTLOOK Idiopathic pulmonary fibrosis (IPF) is a type of lung disease characterized by the thickening and stiffening of tissues in the lungs. While the prognosis for patients diagnosed with…
The HIV therapy market is crowded with many approved antiretroviral therapies (ARVs). Growth in this market is being driven by the increasing acceptance of new, high-priced ARVs, particularly the…
Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of …
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key thyroid cancer patient populations covering 171 countries and more than…
Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to…
In 2019, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast…
In 2019, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $3.98 billion in the major pharmaceutical markets under study (…